Weighing The Options In Medical Abortion.

Medscape women's health Pub Date : 1997-09-01
Schaff, Eisinger, Stadalius
{"title":"Weighing The Options In Medical Abortion.","authors":"Schaff,&nbsp;Eisinger,&nbsp;Stadalius","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>For women who require interruption of pregnancy, medications that can offer a safe alternative to surgery--for example, methotrexate (though interruption of pregnancy is not an approved indication) and mifepristone (formerly known as RU486 and currently pending approval by the Food and Drug Administration [FDA])--are being examined. As with any new therapy, clinicians who wish to be able to offer this option should become familiar with the medications' safety and efficacy profiles and how they work, which patients are acceptable candidates, how the procedure is performed, how to counsel women seeking information, and how to manage complications. Nonsurgical abortion using either methotrexate or mifepristone in combination with misoprostol can be a safe and effective alternative to surgical abortion if a woman is no more than 7 weeks pregnant, clinical guidelines are followed, and access to surgical abortion is available for complications. Administration of either agent is followed within days by administration of misoprostol, a prostaglandin that induces uterine contraction and expulsion of the uterine contents. Side effects of all 3 agents are generally mild, but complications may include ongoing pregnancy, incomplete abortion, or excessive bleeding.</p>","PeriodicalId":79687,"journal":{"name":"Medscape women's health","volume":"2 9","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"1997-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medscape women's health","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

For women who require interruption of pregnancy, medications that can offer a safe alternative to surgery--for example, methotrexate (though interruption of pregnancy is not an approved indication) and mifepristone (formerly known as RU486 and currently pending approval by the Food and Drug Administration [FDA])--are being examined. As with any new therapy, clinicians who wish to be able to offer this option should become familiar with the medications' safety and efficacy profiles and how they work, which patients are acceptable candidates, how the procedure is performed, how to counsel women seeking information, and how to manage complications. Nonsurgical abortion using either methotrexate or mifepristone in combination with misoprostol can be a safe and effective alternative to surgical abortion if a woman is no more than 7 weeks pregnant, clinical guidelines are followed, and access to surgical abortion is available for complications. Administration of either agent is followed within days by administration of misoprostol, a prostaglandin that induces uterine contraction and expulsion of the uterine contents. Side effects of all 3 agents are generally mild, but complications may include ongoing pregnancy, incomplete abortion, or excessive bleeding.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
权衡药物流产的选择。
对于需要中断妊娠的妇女,正在研究可以提供安全替代手术的药物,例如甲氨蝶呤(尽管中断妊娠不是批准的适应症)和米非司酮(以前称为RU486,目前正在等待美国食品和药物管理局的批准)。与任何新疗法一样,希望能够提供这种选择的临床医生应该熟悉药物的安全性和有效性概况以及它们是如何工作的,哪些患者是可接受的候选人,如何进行手术,如何向寻求信息的妇女提供咨询,以及如何处理并发症。甲氨蝶呤或米非司酮联合米索前列醇非手术流产可以是一种安全有效的替代手术流产的方法,如果妇女怀孕不超过7周,遵循临床指南,并可获得手术流产的并发症。服用任何一种药物后,在几天内服用米索前列醇,这是一种前列腺素,可诱导子宫收缩并排出子宫内容物。这三种药物的副作用一般都很轻微,但并发症可能包括持续妊娠、不完全流产或大出血。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Management of hypertensive emergencies of pregnancy by hydralazine bolus injection vs continuous drip--a comparative study. Insulin and oral antidiabetic agents for treatment of polycystic ovary syndrome. Leptin--a new member of the bone builders' club? Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1